Breaking news

“You measure a democracy by the freedom it gives its dissidents, more In one of the biggest leaks ever of offshore financial records, the more The Champaran Foundation, in collaboration with InFeed, is inviting entries more The recently concluded German elections on September 26, 2021 have given a more According to latest news reports, China has been on a defense infrastructure more A new line of argument has already come to dominate the public sphere: it’ more The government has gone one step further to detect community spread of the more The government has issued an order to abolish the six allowances, including more Aarogya Setu application launched by NIC is aimed to track COVID-19 affected more SEOUL| South Korea’s unemployment rate was unchanged in April as the more Amid the outbreak of Corona pandemic in the country, Indian government has more Prime Minister Narendra Modi in his address to the nation on Tuesday indicated more Corona infection in the country is taking a macabre form. So far, more than 74 more Congress General Secretary Priyanka Gandhi Vadra has written a letter to UP more On Tuesday, Prime Minister Narendra Modi announced a package of Rs 20 lakh more

Russia to Roll Out First Corona Drug By Next Week

Avifavir Russia

Russia has its first drug approved to treat Covid-19, Avifavir and will start giving it to the patients from next week. This may help reduce the strain on the health and the economic life of Russia.

Avifavir is an anti-influenza medication. It has been repurposed to  fight COVID-19. Preliminary trials are said to have shown that Avifavir could shorten recovery times for patients with the coronavirus. It is being said that Russian hospitals will begin the medication from June 11. The company manufacturing this drug will manufacture enough to treat around 60,000 people per month.

Russia’s Ministry of Health approved Avifavir on May 30, for emergency use to treat COVID-19, after “encouraging” results from clinical trials of the drug (generic version: Favipiravir) in several countries, including China and Japan. It is Russia’s first COVID-19 drug.

This can be a landmark in treating Corona as currently there is no vaccination of COVID-19, however several attempts have been made including HCQ, and this can certainly help in reducing the recovery time, as reports suggest.

Avifavir is based on Favipiravir, and originally sold in Japan under the brand name Avigan. It was developed by Japan’s Fujifilm Pharmaceuticals, approved in 2014, as an antiviral medication to treat influenza.

Favipiravir is a pyrazinecarboxamide derivative, and is also being studied to treat a number of other viral infections.

Favipiravir works by blocking the ability of a virus to replicate inside a cell. Some doctors began trying Favipiravir to treat coronavirus patients early on, reasoning that its anti-viral properties would be applicable.

Initial results suggested the drug could help shorten recovery time for patients.

Russian scientists had modified the drug to enhance it, and Moscow would be ready to share the details, said RDIF head Kirill Dmitriev.

Avifavir appeared on a Russian government list of approved drugs on Saturday.

Accelerated process

Dmitriev said clinical trials of the drug had been conducted involving 330 people, and had shown that it successfully treated the virus in most cases within four days.

The trials were due to be concluded in around a week, he said, but the health ministry had given its approval for the drug’s use under a special accelerated process and manufacturing had begun in March.

With 414,878 cases, Russia has the third highest number of infections in the world after Brazil and the United States, but has a relatively low official death toll of 4,855 – something that has been the focus of debate.

RDIF, which has a 50 per cent share in the drug’s manufacturer ChemRar, funded the trials and other work with its partners, to the tune of around 300 million roubles ($4.3 million), said Dmitriev, who explained that the costs to Russia were much lower because of previous development work conducted in Japan.


Story Page